Forte Biosciences Inc (FBRX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Forte Biosciences Inc   (NASDAQ: FBRX)


Forte Biosciences Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Forte Biosciences Inc's ROI in the second quarter of 2026?
Forte Biosciences Inc recorded a cumulative net loss of $-88 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -93.76%.

Within the Healthcare sector 612 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2914 to 4070.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 88.63 % 145.93 % 163.43 % 202.92 % 63.87 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 185 44 62 84 99
Return On Investment (TTM) -93.76 % -105.24 % -98 % -75.64 % -85.38 %
FBRX's Overall Ranking # 4070 # 2914 # 3587 # 3257 #
Seq. Investment Change TTM 30.12 % 1.82 % 3.49 % 37.57 % 69.65 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -88 -76 -69 -52 -42




Return On Investment FBRX's Ranking
Within: No.
Industry # 276
Sector # 613
Overall # 4070

Return On Investment Statistics
High Average Low
-26.24 %
-111.77 %
-703.91 %
(Jun 30 2021)   (Jun 30 2020)







Financial Statements
Forte Biosciences Inc's II. Quarter Investments $ 185 Millions FBRX's Balance sheet
Forte Biosciences Inc's II. Quarter Income $ -23 Millions Quarterly FBRX's Income Statement
FBRX's Income by Division See FBRX's Income by Division


FBRX Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 62 52 35 39 42
Y / Y Investment Growth 18.19 % 48.61 % -9.03 % -6.57 % -29.56 %
Net Income in Millions -69 -35 -31 -14 -22
Y / Y Net Income Growth - - - - -
Annual Return On Investment -111.84 % -67.6 % -89.13 % -35.75 % -52.25 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
FBRX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for FBRX's Competitors
Subscribers only: Roi for Forte Biosciences Inc's Suppliers
Subscribers only: Return On Investment for FBRX's Customers

Other Ratios
FBRX's Roa FBRX's Inventory Turnover Ratio FBRX's Growth Rates FBRX's Dividend Statistics
FBRX's Profitability Ratios FBRX's Asset Turnover Ratio FBRX's Dividend Growth
FBRX's Roe FBRX's Valuation Ratios FBRX's Financial Strength Ratios FBRX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI


Date modified: 2026-09-03T23:44:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.